ROLE OF INTRAVITREAL RANIBIZUMAB IN EALE'S DISEASE WITH MILD VITREOUS HEMORRHAGE AND MACULAR EDEMA : A RETROSPECTIVE STUDY.

Kaushik Sadhukhan; Subhrajyoti Naskar; Dhritashree Mandal; Ankita Das

Volume : VIII, Issue : XII, December - 2019

ROLE OF INTRAVITREAL RANIBIZUMAB IN EALE'S DISEASE WITH MILD VITREOUS HEMORRHAGE AND MACULAR EDEMA : A RETROSPECTIVE STUDY.

Kaushik Sadhukhan, Subhrajyoti Naskar, Dhritashree Mandal, Ankita Das

Abstract :

AIM: To evaluate the role of intravitreal Ranibizumab in resolution of mild vitreous hemorrhage along with macular edema in Eale�s disease. METHODOLOGY: This retrospective interventional nonrandomized study was conducted in Malda Medical College, West Bengal from January 2017 to December 2018 having included 16 eyes of 16 patients with Eale�s disease. After proper clinical evaluation and required investigations, all patients received 3 consecutive doses of intravitreal Ranibizumab at 1 month interval under topical anaesthesia and strict aseptic measures along with routine systemic and periocular steroid therapy. Patients were followed up at 1 month and 3 months after the 1st dose of injection and at each visit, best corrected visual acuity(BCVA)by standard snellen�s chart, intraocular pressure(IOP) measurement by Goldmann�s applanation tonometer, extenct of vitreous hemorrhage, central macular thickness (CMT) measurement by spectral domain optical coherence tomography(SD–OCT) were recorded. All the statistical data were then analysed using paired t test with the help of SPSS software. RESULTS: All but one patients had shown improvement in terms of resolution of vitreous hemorrhage and macular edema thus enhancing vision. CONCLUSION: Intravitreal Ranibizumab can be a credible agent to deal with mild vitreous hemorrhage and macular edema associated with Eale�s disease.